$ACON
Aclarion, Inc.

2024 Q3 Form 10-Q Financial Statement

#000168316824005682 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $14.41K $10.97K
YoY Change -24.43% -35.74%
Cost Of Revenue $21.33K $23.29K
YoY Change 9.07% 20.69%
Gross Profit -$6.925K -$12.32K
YoY Change 1304.67% 452.85%
Gross Profit Margin -48.07% -112.32%
Selling, General & Admin $1.093M $921.1K
YoY Change 13.47% -20.18%
% of Gross Profit
Research & Development $195.8K $202.1K
YoY Change -1.24% -19.16%
% of Gross Profit
Depreciation & Amortization $45.76K
YoY Change 13.16%
% of Gross Profit
Operating Expenses $1.289M $1.123M
YoY Change 10.96% -20.0%
Operating Profit -$1.296M -$1.136M
YoY Change 11.51% -19.25%
Interest Expense -$102.5K
YoY Change -317.42%
% of Operating Profit
Other Income/Expense, Net -$70.22K -$102.5K
YoY Change -142.77% 75.67%
Pretax Income -$1.366M -$1.238M
YoY Change 36.89% -15.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.366M -$1.238M
YoY Change 36.89% -15.46%
Net Earnings / Revenue -9482.72% -11285.0%
Basic Earnings Per Share -$0.15 -$0.15
Diluted Earnings Per Share -$0.15 -$0.15
COMMON SHARES
Basic Shares Outstanding 8.611M shares 8.204M shares
Diluted Shares Outstanding 9.438M shares 8.217M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.223M
YoY Change 103.78%
Cash & Equivalents $1.312M $1.173M
Short-Term Investments $50.00K
Other Short-Term Assets $609.4K
YoY Change 238.53%
Inventory
Prepaid Expenses
Receivables $16.95K $19.71K
Other Receivables $0.00
Total Short-Term Assets $1.897M $1.852M
YoY Change 419.89% 132.02%
LONG-TERM ASSETS
Property, Plant & Equipment $892.00 $1.189K
YoY Change -56.76% -49.23%
Goodwill
YoY Change
Intangibles $1.290M $1.236M
YoY Change 9.66% 2.64%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.291M $1.237M
YoY Change 9.54% 2.54%
TOTAL ASSETS
Total Short-Term Assets $1.897M $1.852M
Total Long-Term Assets $1.291M $1.237M
Total Assets $3.188M $3.089M
YoY Change 106.58% 54.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $331.8K $179.1K
YoY Change -51.65% -70.52%
Accrued Expenses $448.0K
YoY Change 191.26%
Deferred Revenue
YoY Change
Short-Term Debt $777.1K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $678.3K $1.447M
YoY Change -71.4% -27.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $678.3K $1.447M
Total Long-Term Liabilities $0.00
Total Liabilities $678.3K $1.447M
YoY Change -71.38% -27.3%
SHAREHOLDERS EQUITY
Retained Earnings -$49.27M -$47.92M
YoY Change 14.54% 14.04%
Common Stock $100.00 $82.00
YoY Change 21.95% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.510M $1.642M
YoY Change
Total Liabilities & Shareholders Equity $3.188M $3.089M
YoY Change 106.58% 54.1%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$1.366M -$1.238M
YoY Change 36.89% -15.46%
Depreciation, Depletion And Amortization $45.76K
YoY Change 13.16%
Cash From Operating Activities -$1.055M
YoY Change 11.29%
INVESTING ACTIVITIES
Capital Expenditures $93.82K
YoY Change 54.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$93.82K
YoY Change 54.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 188.4K
YoY Change -83.82%
NET CHANGE
Cash From Operating Activities -1.055M
Cash From Investing Activities -93.82K
Cash From Financing Activities 188.4K
Net Change In Cash -959.9K
YoY Change -713.15%
FREE CASH FLOW
Cash From Operating Activities -$1.055M
Capital Expenditures $93.82K
Free Cash Flow -$1.148M
YoY Change 13.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
406094 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
202102 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49560800 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47918705 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1642177 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3088821 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2024Q1 ACON Cashless Exercise Of Prefunded Warrant
CashlessExerciseOfPrefundedWarrant
usd
CY2024Q1 ACON Round Up Conversion Related To Reverse Stock Split
RoundUpConversionRelatedToReverseStockSplit
usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41358
dei Entity Registrant Name
EntityRegistrantName
ACLARION, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324725
dei Entity Address Address Line1
EntityAddressAddressLine1
8181 Arista Place
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Broomfield
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80021
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
275-2266
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8610671 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1021069 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
10000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13270 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
245030 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1289369 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1782 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1168623 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1170405 usd
CY2023Q4 us-gaap Assets
Assets
2459774 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
760535 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
857722 usd
CY2023Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
1125724 usd
CY2023Q4 ACON Warrant Liability Current
WarrantLiabilityCurrent
289165 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
121326 usd
CY2023Q4 ACON Liability To Issue Equity
LiabilityToIssueEquity
33297 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3187769 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3187769 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8210671 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8210671 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
825459 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
825459 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43553523 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44281526 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-727995 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2459774 usd
CY2024Q2 us-gaap Revenues
Revenues
10971 usd
CY2023Q2 us-gaap Revenues
Revenues
17072 usd
us-gaap Revenues
Revenues
21085 usd
us-gaap Revenues
Revenues
42542 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
23294 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
19301 usd
us-gaap Cost Of Revenue
CostOfRevenue
42770 usd
us-gaap Cost Of Revenue
CostOfRevenue
36754 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
-12323 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
-2229 usd
us-gaap Gross Profit
GrossProfit
-21685 usd
us-gaap Gross Profit
GrossProfit
5788 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
225037 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
207790 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
385074 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
250006 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
441143 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
454405 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
696099 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
946175 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1541947 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1753774 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1123238 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1403971 usd
us-gaap Operating Expenses
OperatingExpenses
2389184 usd
us-gaap Operating Expenses
OperatingExpenses
2593253 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1135561 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1406200 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2410869 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2587465 usd
CY2024Q2 us-gaap Interest Expense Other
InterestExpenseOther
127848 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
47139 usd
us-gaap Interest Expense Other
InterestExpenseOther
463672 usd
us-gaap Interest Expense Other
InterestExpenseOther
48519 usd
CY2024Q2 ACON Loss On Exchange Of Debt
LossOnExchangeOfDebt
-0 usd
CY2023Q2 ACON Loss On Exchange Of Debt
LossOnExchangeOfDebt
-0 usd
ACON Loss On Exchange Of Debt
LossOnExchangeOfDebt
1066732 usd
ACON Loss On Exchange Of Debt
LossOnExchangeOfDebt
-0 usd
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-111928 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
25357 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-11800 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
323041 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-11800 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
583 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92980 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-234 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-102516 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-58356 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1226311 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-60552 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1238077 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1464557 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3637180 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2648017 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1238077 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1464557 usd
us-gaap Net Income Loss
NetIncomeLoss
-3637180 usd
us-gaap Net Income Loss
NetIncomeLoss
-2648017 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1238077 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1464557 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3637180 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2648017 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.83
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.22
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8217024 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8217024 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
517979 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
517979 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6829825 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6829825 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
507499 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
507499 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2225958 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
82531 usd
CY2023Q1 ACON Proceeds From Sale Of Series Preferred Stock
ProceedsFromSaleOfSeriesPreferredStock
1000 usd
CY2023Q1 ACON Redemption Of Series Preferred Stock
RedemptionOfSeriesPreferredStock
-1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1183460 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1125029 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
136631 usd
CY2023Q2 ACON Commitment Shares Note Financing
CommitmentSharesNoteFinancing
175619 usd
CY2023Q2 ACON Issuance Of Warrants Note Financing
IssuanceOfWarrantsNoteFinancing
37500 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1464557 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10223 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-727995 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85827 usd
CY2024Q1 ACON Issuance Of Common Shares Equity Line Of Credit
IssuanceOfCommonSharesEquityLineOfCredit
1449532 usd
CY2024Q1 ACON Issuance Of Commitment Shares Note Financing
IssuanceOfCommitmentSharesNoteFinancing
33297 usd
CY2024Q1 ACON Issuance Of Common Stock And Warrants Related To Public Offering Net Issuance Costs
IssuanceOfCommonStockAndWarrantsRelatedToPublicOfferingNetIssuanceCosts
2691391 usd
CY2024Q1 ACON Public Offering And Line Of Credit Issuance Costs
PublicOfferingAndLineOfCreditIssuanceCosts
-399106 usd
CY2024Q1 ACON Issuance Of Common Shares Debt For Equity Exchange
IssuanceOfCommonSharesDebtForEquityExchange
1771606 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2399102 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2505449 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
70305 usd
CY2024Q2 ACON Issuance Of Common Shares Equity Line Of Credit
IssuanceOfCommonSharesEquityLineOfCredit
304500 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1238077 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1642177 usd
us-gaap Net Income Loss
NetIncomeLoss
-3637180 usd
us-gaap Net Income Loss
NetIncomeLoss
-2648017 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90864 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79809 usd
us-gaap Share Based Compensation
ShareBasedCompensation
156131 usd
us-gaap Share Based Compensation
ShareBasedCompensation
219162 usd
ACON Gain Loss On Exchange Of Debt
GainLossOnExchangeOfDebt
1066732 usd
ACON Gain Loss On Exchange Of Debt
GainLossOnExchangeOfDebt
0 usd
ACON Gains Losses On Extinguishment Of Debts
GainsLossesOnExtinguishmentOfDebts
111928 usd
ACON Gains Losses On Extinguishment Of Debts
GainsLossesOnExtinguishmentOfDebts
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
442289 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28520 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-323041 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
11800 usd
ACON Noncash Interest Related To Bridge Funding
NoncashInterestRelatedToBridgeFunding
49116 usd
ACON Noncash Interest Related To Bridge Funding
NoncashInterestRelatedToBridgeFunding
14346 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5115 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1414 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
405657 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33287 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-540710 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
57914 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-267325 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
241110 usd
ACON Increase Decrease In Note Payable Net Of Discount
IncreaseDecreaseInNotePayableNetOfDiscount
-31129 usd
ACON Increase Decrease In Note Payable Net Of Discount
IncreaseDecreaseInNotePayableNetOfDiscount
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3293096 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1960653 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
157523 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
72634 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157523 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72634 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2691391 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1754032 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300973 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
ACON Equity Line Of Credit Issuance Costs
EquityLineOfCreditIssuanceCosts
262744 usd
ACON Equity Line Of Credit Issuance Costs
EquityLineOfCreditIssuanceCosts
-0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
256094 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
ACON Bridge Funding Issuance Costs
BridgeFundingIssuanceCosts
23375 usd
ACON Bridge Funding Issuance Costs
BridgeFundingIssuanceCosts
85000 usd
ACON Proceeds From Bridge Funding
ProceedsFromBridgeFunding
0 usd
ACON Proceeds From Bridge Funding
ProceedsFromBridgeFunding
1250000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1000 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
-0 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
1000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3602237 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1165000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
151618 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-868287 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1031069 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1482806 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1182687 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
614518 usd
ACON Issuance Of Common Shares In Exchange For Debt
IssuanceOfCommonSharesInExchangeForDebt
1519779 usd
ACON Issuance Of Common Shares In Exchange For Debt
IssuanceOfCommonSharesInExchangeForDebt
0 usd
ACON Issuance Of Bridge Fund Commitment Shares
IssuanceOfBridgeFundCommitmentShares
33297 usd
ACON Issuance Of Bridge Fund Commitment Shares
IssuanceOfBridgeFundCommitmentShares
175619 usd
ACON Fair Value Of Warrants And Derivative Related To Bridge Funding
FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding
0 usd
ACON Fair Value Of Warrants And Derivative Related To Bridge Funding
FairValueOfWarrantsAndDerivativeRelatedToBridgeFunding
742988 usd
ACON Accrued Debt Issuance Costs Related To Bridge Funding
AccruedDebtIssuanceCostsRelatedToBridgeFunding
0 usd
ACON Accrued Debt Issuance Costs Related To Bridge Funding
AccruedDebtIssuanceCostsRelatedToBridgeFunding
118575 usd
ACON Issuance Of Warrants Related To Bridge Funding
IssuanceOfWarrantsRelatedToBridgeFunding
0 usd
ACON Issuance Of Warrants Related To Bridge Funding
IssuanceOfWarrantsRelatedToBridgeFunding
37500 usd
ACON Original Issue Discount15 Related To Bridge Funding
OriginalIssueDiscount15RelatedToBridgeFunding
0 usd
ACON Original Issue Discount15 Related To Bridge Funding
OriginalIssueDiscount15RelatedToBridgeFunding
187500 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_ziG9kpLZ5Bff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_867_zn4BPLb1gMOa">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and valuation of warrants, warrant and derivative liabilities, and options to purchase shares of the Company's common stock. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p id="xdx_841_eus-gaap--DerivativesReportingOfDerivativeActivity_zVoH8tcJ5E1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_z3ko8Qu0N10l">Derivative Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expenses), on a net basis in the Consolidated Statements of Operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
818591 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
761800 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
10000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
42462 usd
CY2023Q4 us-gaap Fair Value Hedge Liabilities At Fair Value
FairValueHedgeLiabilitiesAtFairValue
410491 usd
ACON Exchange And Payoff Of Notes Payable
ExchangeAndPayoffOfNotesPayable
-44988 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-323041 usd
CY2024Q2 us-gaap Fair Value Hedge Liabilities At Fair Value
FairValueHedgeLiabilitiesAtFairValue
42462 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
649357 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
245030 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
179123 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
760535 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
447972 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
857722 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2429790 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2272268 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1193915 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1103645 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1235875 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1168623 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
45458 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
39940 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
90270 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
78805 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
96015 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
192030 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
192030 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
192030 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
563770 usd
CY2024Q2 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
1235875 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q4 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
296313 usd
CY2023Q4 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
320561 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
862500 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
2594118 usd
CY2024Q2 ACON Unamortized Discounts And Deferred Financing Costs Warrants
UnamortizedDiscountsAndDeferredFinancingCostsWarrants
0 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Warrants
UnamortizedDiscountsAndDeferredFinancingCostsWarrants
-557582 usd
CY2024Q2 ACON Unamortized Discounts And Deferred Financing Costs Derivative
UnamortizedDiscountsAndDeferredFinancingCostsDerivative
-34475 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Derivative
UnamortizedDiscountsAndDeferredFinancingCostsDerivative
-235628 usd
CY2024Q2 ACON Unamortized Discounts And Deferred Financing Costs Issuance Cost
UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost
-50938 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Issuance Cost
UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost
-675184 usd
CY2024Q2 ACON Unamortized Discounts And Deferred Financing Costs Total
UnamortizedDiscountsAndDeferredFinancingCostsTotal
-85413 usd
CY2023Q4 ACON Unamortized Discounts And Deferred Financing Costs Total
UnamortizedDiscountsAndDeferredFinancingCostsTotal
-1468394 usd
CY2024Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
777087 usd
CY2023Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
1125724 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8210671 shares
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
1000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-1238077 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1464557 usd
CY2024Q2 ACON Weighted Average Number Of Shares Outstanding Basic1
WeightedAverageNumberOfSharesOutstandingBasic1
8208281 shares
CY2023Q2 ACON Weighted Average Number Of Shares Outstanding Basic1
WeightedAverageNumberOfSharesOutstandingBasic1
505485 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8743 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
12494 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8217024 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8217024 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
517979 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
517979 shares
us-gaap Profit Loss
ProfitLoss
-3637180 usd
us-gaap Profit Loss
ProfitLoss
-2648017 usd
ACON Weighted Average Number Of Shares Outstanding Basic1
WeightedAverageNumberOfSharesOutstandingBasic1
6817419 shares
ACON Weighted Average Number Of Shares Outstanding Basic1
WeightedAverageNumberOfSharesOutstandingBasic1
498415 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
12406 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9084 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6829825 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6829825 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
507499 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
507499 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10840985 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
434362 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169456 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.15
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169456 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
147977 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.57
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
154971 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
70305 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
136631 usd
us-gaap Share Based Compensation
ShareBasedCompensation
156131 usd
us-gaap Share Based Compensation
ShareBasedCompensation
219162 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-005682-index-headers.html Edgar Link pending
0001683168-24-005682-index.html Edgar Link pending
0001683168-24-005682.txt Edgar Link pending
0001683168-24-005682-xbrl.zip Edgar Link pending
aclarion_ex3101.htm Edgar Link pending
aclarion_ex3102.htm Edgar Link pending
aclarion_ex3201.htm Edgar Link pending
aclarion_ex3202.htm Edgar Link pending
aclarion_i10q-063024.htm Edgar Link pending
acon-20240630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
acon-20240630_cal.xml Edgar Link unprocessable
acon-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aclarion_i10q-063024_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acon-20240630_lab.xml Edgar Link unprocessable
acon-20240630_def.xml Edgar Link unprocessable